Zepbound vs Trulicity: Side-Effect Profile Head-to-Head

How These Two Drugs Differ at the Receptor Level

Zepbound (tirzepatide) activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. Trulicity (dulaglutide) acts on the GLP-1 receptor alone. That pharmacological distinction matters for side effects because GIP receptor activation adds a separate signaling cascade that influences gastric motility, appetite regulation, and fat metabolism differently than GLP-1 alone.

Tirzepatide was engineered as a single molecule with roughly five-fold higher affinity for the GIP receptor than for GLP-1, according to its FDA prescribing information. Dulaglutide, by contrast, is a GLP-1 analog fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days [1]. Both drugs slow gastric emptying, but tirzepatide's dual action appears to amplify that effect at higher doses. The result: more pronounced GI side effects, but also substantially more weight reduction.

No head-to-head randomized trial has directly compared Zepbound and Trulicity for side effects. The comparisons below synthesize adverse event data reported across the SURMOUNT program for tirzepatide and the REWIND trial and AWARD program for dulaglutide. Cross-trial comparisons carry limitations, including different patient populations, dose ranges, and follow-up durations. That caveat applies throughout this article.

Gastrointestinal Side Effects: The Biggest Differentiator

GI adverse events are the most common reason patients stop either drug. Both tirzepatide and dulaglutide cause nausea, vomiting, diarrhea, and constipation, but rates diverge meaningfully at higher doses of tirzepatide.

In SURMOUNT-1 (N=2,539), nausea occurred in 24.6% of patients on tirzepatide 5 mg, 33.3% on 10 mg, and 31.0% on 15 mg, compared with 9.5% on placebo [2]. Diarrhea rates ranged from 18.7% to 21.1% across tirzepatide dose groups. Vomiting affected 5.7% to 12.2% of tirzepatide-treated patients. Most GI events were mild to moderate in severity and occurred during the dose-escalation period (the first 20 weeks), declining substantially after reaching maintenance dose.

For dulaglutide, the AWARD-1 trial reported nausea in 21.2% of patients on 1.5 mg and 12.4% on 0.75 mg over 52 weeks [3]. Diarrhea rates for dulaglutide 1.5 mg were approximately 12-13%, and vomiting occurred in roughly 7-8% of patients. These numbers are notably lower than tirzepatide's top-dose figures.

The clinical implication is straightforward. Patients who tolerated Trulicity's GI profile may still experience new or worse nausea if switching to Zepbound, especially during titration to 10 mg or 15 mg. Slow dose escalation, which both labels recommend, reduces this risk. The Endocrine Society's 2023 clinical practice guideline on pharmacological treatment of obesity recommends gradual titration and dietary modification to mitigate GI intolerance with all GLP-1 receptor agonists [4].

Injection-Site Reactions and Administration Differences

Both Zepbound and Trulicity are delivered via single-dose prefilled pens, injected subcutaneously once weekly. Injection-site reactions (ISRs) are generally mild with both drugs, but patterns differ slightly.

In the SURMOUNT trials, injection-site reactions were reported in approximately 3-5% of tirzepatide-treated patients. The most common complaints were erythema and pruritus at the injection site [2]. Dulaglutide's prescribing information reports ISRs in approximately 1-2% of patients, though post-marketing surveillance suggests the true rate may be modestly higher [5].

Trulicity's pen design has been on the market since 2014 and requires no needle attachment. Zepbound's pen similarly comes pre-attached. Neither drug requires reconstitution. One practical difference: Zepbound is available in six dose strengths (2.5, 5, 7.5, 10, 12.5, and 15 mg), while Trulicity offers four (0.75, 1.5, 3.0, and 4.5 mg). The broader dose range for tirzepatide allows more granular titration, which can help manage side effects by slowing the escalation schedule.

Pancreatitis and Pancreatic Safety

Acute pancreatitis is a recognized but uncommon risk with all GLP-1 receptor agonists. Both Zepbound and Trulicity carry labeling warnings about this risk.

In SURMOUNT-1, acute pancreatitis occurred in 0.1% of tirzepatide-treated patients and 0.1% of placebo patients [2]. The SURPASS program (tirzepatide for type 2 diabetes) reported similarly low rates. For dulaglutide, the REWIND trial (N=9,901, median follow-up 5.4 years) identified acute pancreatitis in 0.4% of the dulaglutide group versus 0.3% of placebo, a non-significant difference [6].

Dr. Ania Jastreboff, lead author of the SURMOUNT-1 trial and associate professor of medicine at Yale School of Medicine, stated in the NEJM publication: "Gastrointestinal events were the most common adverse events and occurred more frequently with tirzepatide, but serious adverse events were balanced between groups" [2].

The practical takeaway: pancreatitis rates are low for both drugs, and neither has shown a statistically significant excess over placebo in randomized trials. Patients with a history of pancreatitis should discuss risk with their prescriber regardless of which agent they use.

Cardiovascular Safety and MACE Outcomes

Trulicity holds a significant advantage in cardiovascular outcome data. The REWIND trial randomized 9,901 patients with type 2 diabetes (31.5% with established cardiovascular disease) to dulaglutide 1.5 mg or placebo over a median 5.4 years. The primary composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death occurred in 12% fewer patients on dulaglutide (HR 0.88 to 95% CI 0.79-0.99, P=0.026) [6]. All-cause mortality was numerically lower but not statistically significant.

The REWIND investigators wrote in The Lancet: "Dulaglutide reduced the composite cardiovascular outcome in people with type 2 diabetes with and without previous cardiovascular disease" [6]. That finding, showing benefit even in a primary prevention population, was unique among GLP-1 receptor agonist cardiovascular outcome trials at the time of publication.

Zepbound does not yet have a completed cardiovascular outcome trial (CVOT). The SURPASS-CVOT study (tirzepatide vs dulaglutide in patients with type 2 diabetes and established atherosclerotic cardiovascular disease) is ongoing and expected to report results in 2027 [7]. The FDA label for Zepbound does not carry a cardiovascular risk warning, but it also lacks the proven CV benefit that dulaglutide established through REWIND.

For patients where cardiovascular risk reduction is a primary treatment goal alongside weight management or glycemic control, Trulicity currently has the stronger evidence base.

Thyroid C-Cell Tumors and the Boxed Warning

Both tirzepatide and dulaglutide carry the same FDA boxed warning regarding the risk of thyroid C-cell tumors, based on rodent studies showing dose-dependent and duration-dependent increases in thyroid C-cell tumors in rats. Neither drug has demonstrated this signal in humans.

The boxed warning states that both drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [5]. Calcitonin monitoring is not recommended for routine clinical use, per Endocrine Society guidelines, because the predictive value of calcitonin screening in this context is low [4].

This is a class-level concern, not a differentiator between the two drugs. It should not drive the choice between Zepbound and Trulicity.

Weight-Related Adverse Events and Body Composition

Greater weight loss introduces its own side-effect considerations. Tirzepatide at 15 mg produced 20.9% mean body-weight loss at 72 weeks in SURMOUNT-1, compared with 3.1% for placebo [2]. Dulaglutide typically produces 2-5% body-weight loss in the AWARD trials, though the 4.5 mg dose (approved in 2020) can push this somewhat higher.

Rapid weight reduction from any cause increases the risk of gallbladder events, including cholelithiasis and cholecystitis. In SURMOUNT-1, cholelithiasis occurred in 0.4% of tirzepatide-treated patients versus 0.2% of placebo [2]. This rate is consistent with other anti-obesity medications that produce >10% weight loss.

Lean mass loss is another consideration with significant weight reduction. A sub-study of the SURMOUNT-1 trial using dual-energy X-ray absorptiometry (DXA) found that approximately 33% of total weight lost with tirzepatide was lean mass [8]. This ratio is comparable to other pharmacological and surgical weight-loss interventions. Resistance training is recommended during GLP-1 agonist therapy to preserve muscle, though clinical trial protocols did not mandate exercise.

For Trulicity, the degree of weight loss is modest enough that gallbladder events and lean mass loss are not clinically prominent concerns in most patients.

Hypoglycemia Risk

Neither Zepbound nor Trulicity carries a high intrinsic risk of hypoglycemia when used without insulin or sulfonylureas. Both drugs stimulate insulin secretion in a glucose-dependent manner, meaning they should not cause insulin release when blood glucose is already in the normal range.

In SURMOUNT-1, clinically significant hypoglycemia (blood glucose <54 mg/dL) occurred in 0.0% to 0.1% of tirzepatide-treated patients who were not on concomitant insulin or sulfonylureas [2]. REWIND reported that severe hypoglycemia occurred in 1.1% of dulaglutide-treated patients versus 0.9% of placebo over 5.4 years, but the majority of these events occurred in patients also taking sulfonylureas or insulin [6].

The bottom line: hypoglycemia is not a meaningful differentiator between these two drugs when either is used as monotherapy or with metformin alone.

Discontinuation Rates Due to Adverse Events

The percentage of patients who stop treatment because side effects are intolerable provides a useful real-world signal. In SURMOUNT-1, treatment discontinuation due to adverse events was 4.3% for tirzepatide 5 mg, 7.1% for 10 mg, and 6.2% for 15 mg, versus 2.6% for placebo [2]. The majority of discontinuations were driven by GI complaints during dose escalation.

For dulaglutide 1.5 mg, discontinuation due to adverse events across the AWARD trials ranged from 4% to 6%, depending on the comparator arm and study duration [3]. REWIND, with its longer follow-up, reported a 6.3% discontinuation rate due to adverse events for dulaglutide versus 4.5% for placebo over 5.4 years [6].

These rates are broadly similar. Tirzepatide at the 10 mg and 15 mg doses trends slightly higher for GI-driven discontinuation, which aligns with its more potent effect on gastric motility. Using the recommended gradual dose escalation (4-week intervals per the label) appears to mitigate this.

Who Should Choose Which Drug

Prescribing decisions between these agents depend on the treatment goal. Zepbound is FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Trulicity is approved for type 2 diabetes management and cardiovascular risk reduction in that population.

A patient with type 2 diabetes and established cardiovascular disease may benefit more from Trulicity's proven MACE reduction. A patient whose primary goal is significant weight loss and who does not have type 2 diabetes would be a better candidate for Zepbound. Patients with a history of severe GI intolerance on other GLP-1 agonists may tolerate dulaglutide's lower nausea rates more easily, though individual response varies considerably.

The 2023 American Association of Clinical Endocrinology (AACE) consensus statement on obesity management recommends tirzepatide as a first-line pharmacotherapy option for patients with BMI ≥30, citing its superior weight-loss efficacy [9]. For patients with type 2 diabetes, AACE recommends considering cardiovascular outcome trial data when selecting a GLP-1 receptor agonist.

Clinicians should discuss both the efficacy differential and the side-effect burden with patients before prescribing, particularly if a patient is switching from one agent to the other.